Fabry's disease.

Abstract

Fabry's disease is an X-linked lysosomal storage disorder caused by abnormalities in the GLA gene, which leads to a deficiency in α-galactosidase A. The abnormal accumulation of glycosphingolipids, primarily globotriaosylceramide, manifests as serious and progressive impairment of renal and cardiac functions. In addition, patients experience pain, gastrointestinal disturbance, transient ischemic attacks and strokes. Disease presentation in female heterozygotes may be as severe as in males although women may also remain asymptomatic. This review covers all basic aspects of the disease such as epidemiology, pathophysiology, clinical presentation by systems, diagnosis, management, prevention, and repercussions on quality of life. With the development of enzyme replacement therapy in the past few years, early initiation of treatment was found to be key for reduction of disease burden in major affected organs with improvement in neuropathic pain, decreased cardiac mass and stabilization of renal function, gastrointestinal symptoms, and hearing. This review aims to raise the awareness of the signs and symptoms of Fabry's disease as well as to provide guidelines for the diagnosis and treatment.

• Authors: Rima El-Abassi, Divya Singhal, John D England
• Journal: Journal of the neurological sciences (J Neurol Sci) Vol. 344 Issue 1-2 Pg. 5-19 (Sep 15 2014) ISSN: 1878-5883 [Electronic] Netherlands
• PMID: 25106696 (Publication Type: Journal Article, Review)
• Copyright: Published by Elsevier B.V.

Topics

• Fabry Disease (complications, diagnosis, therapy)
• Humans